Key result
Immunosuppressive treatment in patients with suspected cardiac sarcoidosis significantly reduced myocardial SUVmax (6.5 to 4.0; P<0.01) and cardiac metabolic volume, with an improvement in LVEF.
Why the study?
The study was conducted to compare the contributions of cardiac MRI and PET, with particular reference to quantitative measures, in the diagnosis and management of cardiac sarcoidosis.
Does immunosuppressive treatment improve FDG PET and cardiac MRI parameters in patients with possible cardiac sarcoidosis?
Population
31 patients with proven extracardiac sarcoidosis and possible cardiac sarcoidosis
Comparison
Cardiac MRI vs FDG PET/CT in treated and untreated patients
Design
Retrospective observational study
Follow-up
Median 228 days
Authors
Loading...
Immunosuppression may benefit suspected cardiac sarcoidosis; leaves open confirmation in randomized trials.
Observational (n=31)
Does immunosuppressive treatment improve FDG PET and cardiac MRI parameters in patients with possible cardiac sarcoidosis?
p-value: p=<.01
FDG PET/CT, specifically cardiac metabolic volume, is a useful objective measure for assessing response to immunosuppressive therapy in cardiac sarcoidosis, correlating with LVEF improvement.
Coulden et al. (2020) conducted an observational in Cardiac sarcoidosis (n=31). Immunosuppressive treatment (corticosteroids) vs. Untreated patients was evaluated on Myocardial SUVmax (p=<.01). Immunosuppressive treatment in patients with suspected cardiac sarcoidosis significantly reduced myocardial SUVmax (6.5 to 4.0; P<0.01) and cardiac metabolic volume, with an improvement in LVEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: